Skip to main content

Table 1 Comparison of UPRmt between cancer cells and normal cells

From: Mitochondrial dysfunction, UPRmt signaling, and targeted therapy in metastasis tumor

  UPRmt in cancer cells UPRmt in normal cells
Cell type All type of the carcinoma cells Post-mitotic cells
Activitor Accumulation unfolded proteins, impaired ETC, mtdna mutation and deletion, inhibition of mitochondrial chaperones or proteases, increased ROS level Accumulation unfolded proteins, impaired ETC, mtDNA mutation and deletion, inhibition of mitochondrial chaperones or proteases, increased ROS level
Regulatory pathway CHOP-, SIR3/7-, Pink-, Nrf-, calcium-, and ATF4/5-mediated signal pathway SIR3/7-, and ATF4/5-mediated signal pathway
Effector FOXOs, HSPs, HIF, ClpP, SOD1/2, MAPK, OXPHOS-related proteins, proteasome, mitochondrial ribosomal protein HSPs, SOD1/2, OXPHOS-related proteins, proteasome
Outcome Cancer proliferation and metastasis Cell longevity and lifespan extension